Added to YB: 2025-08-22
Pitch date: 2025-07-03
IRD [bullish]
Opus Genetics, Inc.
+361%
current return
Author Info
No bio for this author
Company Info
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
Market Cap
$323.7M
Pitch Price
$1.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.26
P/E
-5.71
EV/Sales
19.71
Sector
Biotechnology
Category
growth
Opus Genetics, Inc. - $IRD
IRD: AAV gene therapy for retinal diseases. LCA5 Phase I/II data (3Q25) derisked in adults, BEST1 trial starting 2H25. Both eligible for PRV worth $100M+. $0.95 financing with warrants. Post-BEST1 value ~$300M. Risks: cash burn, RFK FDA, pricing scrutiny. Ex-Spark founders using Luxturna playbook; RMAT designation speeds approval.
Read full article (7 min)